immatics biotechnologies GmbH closes €34 million financing

immatics biotechnologies GmbH conducted another financing round amounting to €34 million. The funding has been secured within the existing investor group.

P+P partner Dr. Michael Inhester advised co-investor EMBL EMBL Technology Fund GmbH & Co.KG, supported by associate Eckhardt Weber.